CannabisNewsWire
Editorial Coverage: All eyes are on Canada and the burgeoning
North American cannabis market as the flood gates open and
nationwide recreational legalization north of the U.S. border
throws the recent $47.3 billion by
2027 forecast from Arcview Market Research into clear
relief.
- Historic end of cannabis prohibition creates unprecedented
market forces
- CBD could outpace broader market
- Direct selling in the digital age more relevant than ever
- Overlapping cultural vectors among core wellness and cannabis
consumers
- Biopharma potential immense, nutritional potential immediately
accessible commercially
Already running hot at $9.2 billion last year, the North
American cannabis market appears to be just getting started.
Youngevity International, Inc. (NASDAQ: YGYI) (YGYI
Profile) is a particularly interesting player in this
space that deserves further examination considering the company’s
strong logistical footprint in direct selling, the success of a
shrewd and comprehensive growth model in ground coffee retail, and
an established presence as one of the most trusted names in
nutritional supplements. INSYS Therapeutics, Inc. (NASDAQ:
INSY) has a leading position in the development of
pharmaceutical cannabinoids. Developers of MARINOL, the first
synthetic tetrahydrocannabinol (THC) oral solution, AbbVie
Inc. (NYSE: ABBV) has been ranked in the top five on
Science magazine's annual list of Top Science Employers.
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) is
known for transdermal cannabinoid therapies and recently reported
the initiation of a first-of-its-kind clinical study using a novel
pharmaceutically produced CBD targeting epilepsy and Fragile X
syndrome. Cara Therapeutics, Inc. (NASDAQ: CARA)
is at the forefront of preclinical work in selective cannabinoid
receptor-modulating formulas that avoid interacting with receptors
in the central nervous system.
To view an infographic of this editorial, click here.
Functional Cannabis Consumables
CBD from sources such as industrial hemp, which would be legal
to cultivate in the United States under the new Farm Bill currently
being considered, could post growth that eclipses that of the
broader cannabis space. A strong driver here is the mounting
laundry list of proven health
benefits of CBD.
Youngevity
International, Inc. (NASDAQ: YGYI) recently announced
the launch of two new organic hemp-derived cannabidiol products
designed to be used with the company’s proprietary portable
water-filtering bottle system. HempFX™ Hydration™ — Sleep has added
melatonin and promotes healthy sleep patterns naturally, while
HempFX Hydration™ — Pure is designed to deliver 25 mg of
full-spectrum CBD directly to the digestive system.
These beverages are now available online and join a growing
portfolio of organic CBD-based products from YGYI, including HempFX
Soothe™ for achy joints and muscles; HempFX Uplift™, which is
designed to naturally elevate mood and promote overall health; and
HempFX Relax™, which is packed with a wide variety of
sleep-supporting botanicals.
The meteoric rise in YGYI’s share price in recent weeks to a
high of $16.25, nearly triple the preceding trend of several years,
was pared somewhat due to broader market declines, leading to an
$11.47 close the week ending Oct 19. However, the market
mini-correction in the latest FOMC meeting, where a steady and
largely anticipated diet of gradual rate hikes was indicated,
appears to have blown off most of its steam according to many
analysts, including those at J.P. Morgan who see a reversal on the horizon as earnings season begins. The
current situation could present a nice buying opportunity, should
the recent upward trend again find traction.
Huge Direct Selling Network, Increasingly Global
Footprint
Q2 2018 saw a 6.6 percent increase in revenues for YGYI to $44.3
million, led by a 23.7 percent jump in coffee sales. With 83
percent of total revenues coming from direct selling (up 3.7
percent) and the remainder coming from coffee, news that the
company is boldly entering the CBD market has set some analysts’
mouths watering. The company’s coffee-roasting segment, run by
wholly owned subsidiary CLR Roasters, has seen tremendous success
with its high-energy, fat-burning JavaFit line of gourmet coffees
as well as the increasingly popular Café La Rica and Josie's Java
House brands.
The same kind of combined marketing, distribution, sourcing and
branded product expertise YGYI has demonstrated in mastery of the
coffee game could put investors in the pole position as the company
goes cannabis, especially amid a political environment where
antiquated regulations are hastily going up in smoke.
In a deal further cementing YGYI’s foothold in the hospitality
market, the company recently signed a massive new
deal with a major operator in the cruise line industry that
will put YGYI’s coffees in the bellies of the entire crew of a
60-ship fleet, as well as those of passengers on three luxury
cruise ships. Youngevity has quickly built out a comprehensive
coffee revenue pipeline encompassing green coffee distribution,
private-label roasting and sales of owned brands, significantly
enabled by an existing direct sales matrix of high-value
relationships. This direct sales network is backed by an
increasingly sophisticated web platform, which is helping YGYI’s
expansion into global markets proceed apace of expectations.
Following Field-to-Cup Coffee Model
Youngevity’s unique field-to-cup
approach to the coffee market, including sourcing its coffees
from an expanding footprint in the high-mountain region of
Nicaragua known for producing exceptional beans, is something the
company is dedicated to emulating as it enters the cannabis
market.
From the CLR Roasters plantations in Matagalpa, Nicaragua, to
the company’s state-of-the-art 40,000-square-foot roasting,
grinding, packaging facility and headquarters in Miami, Youngevity
has mapped out a field-to-cup coffee bean road show that has met
unparalleled success. With an abundance of cultural overlap among
the company’s highest priority consumer segments and a solid
reputation with nutraceutical and healthy lifestyle consumers, YGYI
is leveraging both its assets and experience as it migrates into
functional cannabis foods. Looking at its overall nutritional
product assortment, the company seems to understand the importance
of high-quality raw materials as it relates to developing brand
loyalty among these highly sought-after demos.
Direct Selling Prowess Key to Future
Youngevity has established an enviable presence in the North
American direct selling market, with a sizeable chunk of a growing $37.8 billion empire that is staffed by
an army of some 18.6 million direct selling representatives.
Innovations such as the company’s YoungevityGo2 app, which empowers
distributors with a considerable promotional and management engine
that fits in their pockets, has helped the company secure a
formidable legion of dedicated direct sellers.
With such a robust direct selling model that spills over into
e-commerce and social selling, it should come as no surprise that
Youngevity’s CEO Steve Wallach was recently appointed to the board
of directors at the 200-plus member Direct Selling Association. The
merger of direct selling and cannabis could be a showstopper, and
many investors are looking to YGYI to be where the rubber meets the
road.
Cannabinoids Potential
The nutraceutical and cosmeceutical potential of cannabinoids is
reinforced by the rapidly developing clinical and preclinical
pipelines of a wide variety of companies that are looking to
commercialize indications targeting everything from sleeplessness
and anxiety to epilepsy and cancer.
INSYS Therapeutics, Inc. (NASDAQ: INSY) is
currently working on testing the company’s oral CBD solution in the
treatment of neurocognition and neuroimmune response, as well as
eating behavior and other symptoms. Such work in early psychosis
adds considerable weight to the studies
announced earlier this year, which are using CBD to treat the
symptoms of severe childhood autism. INSYS is also continuing to
support ongoing efforts to study CBD as a treatment for cocaine
dependency.
AbbVie Inc. (NYSE: ABBV) will always have the
record of being first out of the gate with an FDA-approved, cannabis-based drug targeting
nausea and lack of appetite among chemotherapy and AIDS
patients. The company continues to be a contender in the space, due
to the abundance of in-house expertise and facilities, where the
company is forging a new path to the treatment of autoimmune
diseases.
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
made a strong case at the
16th annual International Fragile X Conference for the use of
transdermal CBD gel. Its compelling and statistically significant
data could be a winner for the company and could come to represent
a frontline approach for alleviating the common observable
behaviors Fragile X syndrome presents among children and
adolescents.
Cara Therapeutics, Inc. (NASDAQ: CARA) has
evaluated CR701 in animal model studies where it showed a
significant reversal of enhanced pain response (hyperalgesia) and
the kind of predisposition to increased pain sensitization and
neuronal response to pain (allodynia) experienced among
fibromyalgia patients. CARA has a considerable depth of knowledge
in kappa opioid receptor science when it comes to treating chronic
and acute pain, as well as disease-related itching, with
indications like CR845/difelikefalin and KORSUVA, now both in Phase
3 clinical trials.
Until now, recreational consumer markets such as nutraceuticals
and cosmeceuticals have always been realities perceived only by the
cannabis industry’s over-the-horizon radar. But the potential for
broad-spectrum biopharma indications that could help combat many
incurable or underserved maladies could be an even greater
development than the seemingly inevitable rise of every day
cannabis-infused foods and beverages.
For more information on Youngevity, visit Youngevity
International, Inc. (NASDAQ: YGYI)
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides
(1) access to our news aggregation and syndication servers, (2)
CannabisNewsBreaks that summarize
corporate news and information, (3) enhanced press release
services, (4) social media distribution and optimization services,
and (5) a full array of corporate communication solutions. As a
multifaceted financial news and content distribution company with
an extensive team of contributing journalists and writers, CNW is
uniquely positioned to best serve private and public companies that
desire to reach a wide audience of investors, consumers,
journalists and the general public. CNW has an ever-growing
distribution network of more than 5,000 key syndication outlets
across the country. By cutting through the overload of information
in today’s market, CNW brings its clients unparalleled visibility,
recognition and brand awareness. CNW is where news, content and
information converge.
Receive Text Alerts
from CannabisNewsWire: Text "Cannabis" to
21000
For more information please visit https://www.CannabisNewsWire.com and
or https://CannabisNewsWire.News
Please see full terms of use and disclaimers on the
CannabisNewsWire website applicable to all content provided by CNW,
wherever published or re-published: http://CNW.fm/Disclaimer
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net
DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by CNW are
solely those of CNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable CNW for any investment
decisions by their readers or subscribers. CNW is a news
dissemination and financial marketing solutions provider and is NOT
registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, CNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and CNW undertakes no
obligation to update such statements.
Source:
CannabisNewsWire
Contact:
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Apr 2023 to Apr 2024
